Atorvastatin FXA Impurity is a structurally modified analog of atorvastatin featuring an epoxy-functionalized pyrrolooxazin ring system and a 6-hydroxy substitution on the pyridine core. The compound retains the fluorinated phenyl ring and the ฮฒ-hydroxy acid moiety characteristic of the parent drug but incorporates an epoxide bridge at the pyrrolooxazine junction, coupled with hydroxylation at the 6-position of the heterocyclic framework. This impurity arises via oxidative rearrangement pathways during synthetic processes, introducing stereochemical complexity through the epoxide group. It serves as a critical HPLC reference standard for quantifying degradation-related impurities in atorvastatin formulations.
On RequestCC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)NC4=CC=CC=C4
InChI=1S/C33H34F2N2O5/c1-20(2)31-30(33(42)36-25-6-4-3-5-7-25)29(21-8-12-23(34)13-9-21)32(22-10-14-24(35)15-11-22)37(31)17-16-26(38)18-27(39)19-28(40)41/h3-15,20,26-27,38-39H,16-19H2,1-2H3,(H,36,42)(H,40,41)/t26-,27-/m1/s1
UNKLVVGSJZVOBR-KAYWLYCHSA-N